How (Nasdaq: VBIO) Built A Platform That Could Cover Both Biodefense And Cancer Patients

When a company briefs Pentagon leadership

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored How (Nasdaq: VBIO) Built A Platform That Could Cover Both Biodefense And Cancer Patients Pentagon Briefings, A World-Premier Cancer Center, and a Biodefense Name That's Starting to Get Noticed Valion Bio, Inc. (Nasdaq: VBIO) is quietly building what few small-caps ever achieve: a government-validated platform, multiple active clinical pathways, and its own domestic manufacturing engine. July 22nd Greetings Reader, When a company briefs Pentagon leadership on its technology not once but twice within a matter of weeks, and then a globally recognized cancer institution independently decides to fund and conduct its own clinical trial using that company's drug, paying close attention starts to feel less like speculation and more like standard due diligence. That company is Valion Bio, Inc. (Nasdaq: VBIO). Until April 2026, it was known as Tivic Health Systems, a name that carried a very different story. The corporate rebrand was not cosmetic. It reflected a completed transformation into a late-stage biopharmaceutical company anchored by a TLR5 agonist platform called Entolimod, backed by more than $140Mn in cumulative development funding, and now operating its own U.S.-based biomanufacturing subsidiary. In May 2026, CEO Michael K. Handley briefed senior officials from the U.S. Department of War and BARDA jointly on Entolimod for Acute Radiation Syndrome. That session followed an earlier meeting with Pentagon leadership in April. In both engagements, officials asked for more, with a specific interest in an oral formulation capable of offering operational advantages over injectable countermeasures in mass-casualty scenarios. These are not cold-call meetings. The U.S. House Armed Services Committee's FY27 National Defense Authorization Act report has since directed the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense to develop a concrete prioritization plan for radiation and nuclear countermeasures that function both before and after exposure. That directive aligns almost precisely with what Entolimod was designed to do. Then came the news from Israel. Sheba Medical Center, widely recognized as one of the world's foremost cancer institutions, announced it would self-sponsor a clinical study evaluating Entolimod's capacity to reduce radiation-induced neutropenia and protect healthy tissue in cancer patients undergoing high-dose radiation therapy. Sheba approached Valion Bio directly. It is funding the trial itself. Valion supplies the drug. CEO Michael K. Handley called it, "meaningful external validation of our science." About The Company: Valion Bio Valion Bio, Inc. (Nasdaq: VBIO) is a clinical-stage biopharmaceutical company headquartered in San Antonio, Texas. Its lead asset, Entolimod, is a TLR5 agonist that activates the body's innate immune system through the flagellin receptor pathway, triggering protective responses across both bone marrow tissue and the gastrointestinal tract. This dual-tissue mechanism separates it from existing stockpiled radiation countermeasures like Neupogen and Neulasta, which address only white blood cell recovery. Entolimod carries FDA Fast Track designation and Orphan Drug designation, and is advancing under the FDA's Animal Rule pathway, the regulatory mechanism designed for medical countermeasures where human efficacy trials are not ethically or logistically feasible. That's precisely the situation for a drug built to address mass radiation exposure events. The company's second molecule, Entolasta, is a next-generation TLR5 agonist positioned for oncology supportive care and immune dysfunction, including immunosenescence applications. The company's third potential revenue pillar is Velocity Bioworks, a wholly-owned CDMO subsidiary that opened its San Antonio facility in May 2026 and employs approximately 45 scientists, engineers, and operators. The facility recently completed a 200-fold scale-up of Entolimod production, reaching 50-liter fermentation capacity representing approximately 1.3Mn potential human doses. Velocity Bioworks also pursues third-party biomanufacturing contracts, creating a commercial revenue layer independent of clinical or regulatory milestones. As of Q1 2026, VBIO reported $7.2Mn in cash on its balance sheet, with NIAID committing up to $7Mn in non-dilutive federal funding to complete all remaining BLA-enabling in vivo studies. 6 Potential Catalysts Putting (Nasdaq: VBIO) On Our Watchlist #1. A Float Of Approximately 2.56Mn Shares Makes VBIO A Low Float Name To Watch. With approximately 2.56Mn shares in its float, VBIO qualifies as a low float name where the potential for heightened volatility may be significant, particularly as government procurement dialogue and clinical news continue to develop around the Entolimod platform. #2. Federal Government Now Funds And Co-Navigates VBIO's Path To BLA Filing. NIAID's commitment of up to $7Mn covers all remaining in vivo testing required for VBIO's Biologics License Application. The agency also co-navigates the FDA submission process, adding federal institutional support to the regulatory strategy in a way that company CEO Michael K. Handley described as "a materially different risk profile than a company-sponsored study." #3. House Armed Services Committee's FY27 NDAA Directive Creates Legislative Alignment For VBIO. The FY27 National Defense Authorization Act report now directs the Pentagon to prioritize radiation and nuclear countermeasures with both pre- and post-exposure capability, mapping almost precisely to Entolimod's designed mechanism and the active procurement dialogue VBIO has been building with Department of War and BARDA leadership. #4. Sheba Medical Center's Self-Funded Trial Gives VBIO External Scientific Validation Without Cost. When a world-class institution independently funds and conducts a clinical trial with a company's drug, as Sheba Medical Center is now doing with VBIO's Entolimod, it provides credibility that a company-funded study cannot replicate. Sheba reached out to Valion Bio directly with no financial incentive from the company. #5. Velocity Bioworks Gives VBIO End-To-End Manufacturing Control That Creates A Commercial Moat. Most small-cap biotechs at this stage rely entirely on contract manufacturers. VBIO controls its own 50-liter fermentation production line, has demonstrated 200-fold scale-up capacity, and generates third-party CDMO contract revenue, building structural commercial resilience that is rare at this market capitalization and stage of pipeline development. #6. Multiple Oversold Leaning Technicals Could Be Signaling Potential For A Healthy Reversal. A technical analysis reveals VBIO has several oversold indicators, suggesting a possible reversal setup may be developing. At 3:30PM EST on Tuesday, VBIO had a 9-Day and 14-Day Relative Strength Index both below 27% and a 9-Day and 14-Day Raw Stochastic below 4%. These technical levels suggest a profile that may be currently undervalued. In Closing Valion Bio, Inc. (Nasdaq: VBIO) is a name built at the intersection of national security and clinical science. Entolimod was not born in a startup pitch deck. It emerged from decades of federally funded research, tested across 42 non-human primate studies and evaluated in approximately 300 human subjects. Now the pieces are converging: active federal support, a globally recognized external clinical partner, domestic manufacturing control, and a legislative backdrop that seems written for exactly what this platform was designed to address. Whether or not these developments translate into procurement agreements or near-term regulatory milestones, VBIO has constructed a credibility infrastructure that most clinical-stage biotechs spend years trying to build. The Entolimod story is not done being written. We're officially kicking-off coverage on Valion Bio, Inc. (Nasdaq: VBIO). Be on the lookout for updates heading your way soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice